Medtronic plc

MiniMed Group

The Company has listed on the Nasdaq under the ticker MMED

MiniMed IPO: diabetes monitoring device maker goes public

Generate Biomedicines, Inc.

The Company has listed on Nasdaq under the ticker symbol GENB

IPO Generate Biomedicines: shares of AI drug development platform become available

VolitionRx Limited

Shares of VolitionRx, a micro-cap developer of blood tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;nearly 26% on Tuesday after the company <a href="https://ir.volition.com/news-events/press-releases/detail/874/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution">reported</a>&nbsp;progress in several research programs and said a newly developed cancer-detection method has attracted interest from potential partners. The company also highlighted breakthrough research on detecting lymphoma in cats. Wall Street analysts <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">say</a>&nbsp;the stock could have nearly 790% upside.

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

Arcellx, Inc.

Gilead Sciences, Inc.

Shares of Arcellx, a mid-cap developer of cell therapies for blood cancers, <a href="https://finance.yahoo.com/quote/ACLX/">surged</a>&nbsp;77% on Monday to a new all-time high after the <a href="https://ir.arcellx.com/news/news-details/2026/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel/default.aspx">announcement</a>&nbsp;that its major partner, Gilead Sciences, will acquire the company at a substantial premium to the market price. For investors, the deal signals that leading pharmaceutical companies increasingly prefer full ownership of late-stage oncology assets, Noble <a href="https://www.channelchek.com/news-channel/gilead-to-acquire-arcellx-in-7-8b-bet-on-next-gen-car-t-leadership">argues</a>.

Cancer drugmaker Arcellx explodes 77% in a day as Gilead will acquire it

Recursion Pharmaceuticals, Inc.

ARK Invest, headed by investor Cathie Wood, has increased its stake in small-cap biotech Recursion Pharmaceuticals, which <a href="https://ir.recursion.com/">uses</a>&nbsp;one of the world’s most powerful supercomputers to identify patterns and develop therapies for deadly diseases. The news of Wood's purchase <a href="https://finance.yahoo.com/quote/RXRX/">helped lift</a> the stock more than 5% on Thursday. Earlier, it emerged that chipmaker Nvidia had exited its position in the company.

Cathie Wood increases stake in small-cap biotech Recursion after Nvidia exits

Relmada Therapeutics, Inc.

In 2025, shares of biotech Relmada Therapeutics surged more than 800%. The company executed a strategic pivot after its lead experimental therapy – a program developed for more than 15 years – <a href="https://www.relmada.com/for-investors/news/detail/306/relmada-therapeutics-reports-that-data-monitoring-committee">failed</a> in clinical trials in December 2024. The setback triggered a <a href="https://finance.yahoo.com/quote/RLMD/">sharp selloff</a> in the stock and raised questions about the company’s ability to continue operations. So why does Wall Street <a href="https://www.marketwatch.com/investing/stock/rlmd/analystestimates?mod=mw_quote_tab">now see</a> as much as 140% upside?

Why Wall Street still sees upside in biotech Relmada after 800% growth in 2025

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Risk-tolerant investors should not ignore shares of biotech Viking Therapeutics, Motley Fool analyst Adria Cimino <a href="https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/">argues</a>. This is because the company is developing an obesity drug that could compete with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in the near term.

Motley Fool calls Viking the GLP‑1 drugmaker growth-hunting investors 'can't ignore'

Edgewise Therapeutics, Inc.

Piper Sandler analyst Yasmeen Rahimi has reiterated her "overweight" recommendation on mid-cap biotech Edgewise Therapeutics and called the stock one of the best investment ideas for 2026. She expects the company’s experimental drug to outperform existing treatments in clinical trials, which could give it an advantage in commercialization, the Motley Fool <a href="https://www.fool.com/investing/2026/02/09/why-edgewise-therapeutics-stock-crushed-the-market/">writes</a>.

Why Piper Sandler says biotech Edgewise is a top stock pick in 2026

Janux Therapeutics, Inc.

Legend Biotech Corporation

4D Molecular Therapeutics, Inc.

Arcturus Therapeutics Holdings Inc.

Altimmune, Inc.

Black Diamond Therapeutics, Inc.

The global biotechnology market was valued at about $1.65 trillion in 2025 and is projected to grow to $5.22 trillion by 2034 at a compound annual growth rate of 13.67%, according to <a href="https://straitsresearch.com/report/biotechnology-market">Straits Research</a>. The U.S. market remains the largest globally: it was worth $552.39 billion in 2023 and is expected to reach $1.24 trillion by 2030. Insider Monkey has <a href="https://www.insidermonkey.com/blog/20-best-biotech-stocks-under-20-to-buy-now-1685703/">selected</a>&nbsp;20 biotech companies trading below $20 per share that are widely held by hedge funds.

Insider Monkey names 20 under-$20 biotech stocks popular with hedge funds

Eikon Therapeutics, Inc. Common Stock

The Company has listed on Nasdaq under the ticker EIKN

Eikon IPO: shares of the Merck veteran-led biotech become available

Janux Therapeutics – a small-cap developer of prostate cancer therapies – has lost more than 65% of its market value over the past year. The steepest decline followed the release of data on one of the key candidates in the company’s pipeline. Despite this, Janux shares remain in the portfolios of BlackRock and investor Steve Cohen, according to its <a href="https://www.gurufocus.com/stock/JANX/ownership">Form 13F filing</a> as of the end of September. Wall Street analysts, for their part, continue to recommend buying the stock, expecting it could rise more than 300%.

Why biotech Janux, held by Blackrock and Steve Cohen, has consensus upside of 300%

Veradermics, Incorporated

The Company has listed on the NYSE under the ticker MANE

Biotechnology